ARCHIVES

Troubles of Two Landmark Cancer Drugs, Celebrex and Iressa, Likely to Shape cancer Prevention, FDA Policy. FDA Mulls Withdrawal of Iressa.

This article is from The Cancer Letter archive.

Vol. 31 No. 01 | January 7, 2005

Download PDF Visit The Full Archive

Related Articles

Peter Boyle Elected IARC Director

May 23, 2003

On “Day One Of Post-Genome World,” Eric Lander Recounts 15-Year Journey.

February 16, 2001

Tykerb Plus Herceptin Better Than Monotherapy, Study Says

December 25, 2009

FDA Advisors Recommend Approval Of Taxol for Node-Positive Breast Cancer

September 24, 1999

In Brief: ACS Appoints Directors For Government Relations And Grassroots Development

April 25, 1997

Flood Says Congress Will Renew Cancer Act, But Only After “All Out” Review of Research Policy

December 3, 1976